Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial (Q44452805)

3 December 2017

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial (English)

1 reference

3 December 2017

0 references

Bruce Bode

1

1 reference

3 December 2017

Kaj Stenlöf

2

1 reference

3 December 2017

Daniel Sullivan

3

1 reference

3 December 2017

Albert Fung

4

1 reference

3 December 2017

Keith Usiskin

5

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 April 2013

1 reference

3 December 2017

1 reference

3 December 2017

41

1 reference

3 December 2017

72-84

1 reference

3 December 2017

2

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

3 December 2017

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Biology of human sodium glucose transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Effect of diuretics on the plasma lipid profile

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diab

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1020

21 January 2018

Identifiers

DOI

10.3810/HP.2013.04.1020

1 reference

3 December 2017

1 reference